Home › BioCryst Pharmaceuticals Downgraded to Underperform at Bank of America
 

Keywords :   


BioCryst Pharmaceuticals Downgraded to Underperform at Bank of America

2015-11-16 05:33:57| Biotech - Topix.net

They presently have a $10.00 price target on the biotechnology company's stock, down from their previous price target of $12.00. Bank of America's price objective would indicate a potential upside of 3.95% from the stock's previous close.

Tags: america bank pharmaceuticals downgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
27.09Washington Corner | September 2024
27.09Hurricane Isaac Graphics
27.09Remnants of John Graphics
27.09Remnants of John Forecast Discussion Number 20
27.09Remnants of John Wind Speed Probabilities Number 20
27.09Remnants of John Public Advisory Number 20
27.09Summary for Remnants of John (EP5/EP102024)
27.09Tropical Storm Joyce Graphics
More »